This Article Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Forastiere, A. A. Articles by O'Leary, G. P. Search for Related Content PubMed PubMed Citation Articles by Forastiere, A. A. Articles by O'Leary, G. P., Jr.

Pharmacokinetic and Toxicity Evaluation of Five-Day Continuous Infusion versus Intermittent Bolus cis-Diamminedichloroplatinum(II) in Head and Neck Cancer Patients¹

Department of Medicine, Hematology-Oncology Division, University of Michigan Hospital and Veterans Administration Medical Center, Ann Arbor, Michigan 48105 [A. A. F., W. C. V.]; Departments of Biology and Chemistry, Providence College, Providence, Rhode Island 02918 [J. F. B., G. P. O.]; Department of Pathology and Laboratory Medicine, St. Jude Children's Research Hospital, Memphis, Tennessee 38101 [M. P. G.]; and Department of Medicine, Brown University and Roger Williams General Hospital, Providence, Rhode Island 02908 [M. R. P.]

We administered cis-diamminedichloroplatinum(II), 30 mg/m²/day for 5 days by continuous infusion to six patients with head and neck cancer, and compared the total and filterable plasma concentrations of platinum, and toxic effects, with those observed in five additional patients who received the same dose and schedule of cis-diamminedichloroplatinum(II) by intermittent bolus. In the continuous infusion group, the total 5-day exposure to filterable platinum, determined from the area under the concentration-time curve, was 1.5 to 2-fold higher (P < 0.01) than that observed in the intermittent bolus group although the maximum filterable platinum concentration achieved was 8-fold lower (P < 0.01). These differences were not reflected by total platinum levels. Subclinical nephrotoxicity, as judged by monitoring the urinary excretion of the renal enzymes N-acetyl-ß-D-glucosaminidase and alanine aminopeptidase, as well as ototoxicity, and the incidence and severity of nausea and vomiting were similar in both groups. In contrast, myelosuppression, and hypomagnesemia were more frequent in the continuous-infusion patients, suggesting that the total exposure to free platinum contributes more to these toxicities than peak levels achieved. Considering the clinically acceptable toxicity observed after administration by continuous infusion, we recommend larger therapeutic trials to define the efficacy of increased tumor exposure to filterable platinum.

¹ Supported in part by USPHS Grant 5M01-RR-00042, National Cancer Institute Grants CA-13943-14, and CA-20892-11, and Providence College Fund to Aid Faculty Research.

² To whom requests for reprints should be addressed, at University of Michigan Medical Center, Department of Internal Medicine, Division of Hematology/Oncology, 3119 Taubman Center, P. O. Box 0374, Ann Arbor, MI 48109.

Received 7/ 6/87. Revised 12/28/87. Revised 3/31/88. Accepted 4/ 5/88.

This article has been cited by other articles:

				B. Jeremic, Y. Shibamoto, B. Milicic, N. Nikolic, A. Dagovic, J. Aleksandrovic, Z. Vaskovic, and L. Tadic Hyperfractionated Radiation Therapy With or Without Concurrent Low-Dose Daily Cisplatin in Locally Advanced Squamous Cell Carcinoma of the Head and Neck: A Prospective Randomized Trial J. Clin. Oncol., April 7, 2000; 18(7): 1458 - 1464. [Abstract] [Full Text] [PDF]